Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study (MEMORY)

11. Juli 2017 aktualisiert von: PD Dr. Stephanie Korn, Johannes Gutenberg University Mainz

A Randomized, Double-blind, Placebo-controlled, Mono-center Study to Evaluate the Effects of Mepolizumab on Airway Physiology in Patients With Eosinophilic Asthma: the MEMORY Study

The purpose of the MEMORY trial is to compare the effects of mepolizumab with Placebo on airway physiology in patients with eosinophilic asthma

Studienübersicht

Status

Beendet

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Asthma with eosinophilic inflammation in the airways and/or blood eosinophilia is associated with clinical severity including the risk of exacerbations and relevant comorbidities (e.g. nasal polyposis). Interleukin-5 (IL-5) is a cytokine essential for eosinophil trafficking and survival. Clinical trials of blocking IL-5 with anti-IL-5 antibodies (mepolizumab and reslizumab) in patients with uncontrolled eosinophilic asthma resulted in an improvement in exacerbation rate and oral corticosteroid use. In some studies with mepolizumab and reslizumab there was a beneficial effect on lung function (FEV1). In addition, many patients described a profound impact on asthma symptoms and quality of life in personal reports which is not uniformly reflected in clinical trials.

The MEMORY trial is the first to primarily evaluate the effect of mepolizumab treatment on pulmonary function in patients with severe eosinophilic asthma. Importantly, using spirometry and bodyplethysmography will allow to evaluate additional parameters beyond FEV1 that more closely mirror the pathophysiological changes and functional aspects of airflow limitation in asthma in real life, e.g. airway resistance, hyperinflation and diffusion capacity. The proposed trial will answer the important questions: if, and if so, which parameters of airway (patho-) physiology as assessed by bodyplethysmography best reflect clinical response to mepolizumab therapy in patients with severe eosinophilic asthma. In addition, the time course to clinical response will be assessed. Equally important, there is only a loose correlation between FEV1 and parameters of asthma control and asthma-related quality of life. This is why another new and important aspect of this trial is to carefully monitor asthma control and asthma quality in life in correlation with lung function changes beyond FEV1. Finally, it is tempting to speculate that the proposed trial will contribute to the question how to best define clinical response to mepolizumab.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

29

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Deutschland
      • Mainz, Deutschland, 55131
        • Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Pneumologie

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Patients must be able to give written informed consent prior to participation in the study, which will include the ability to comply with the requirements and restrictions listed in the consent form.
  2. Male or female patients at least 18 years
  3. Physician-diagnosis of asthma and evidence of asthma as documented by either reversibility of airflow obstruction (FEV1 ≥ 12% or 200 ml) demonstrated at visit 1 or visit 2 .
  4. ICS dose must be ≥ 1000 μg/day BDP or equivalent daily with or without maintenance oral corticosteroids.
  5. Treatment in the past 12 months with an additional controller medication for at least 3 successive months, e.g., long-acting beta-2-agonist (LABA), leukotriene receptor antagonist (LTRA), or theophylline.
  6. Persistent airflow obstruction as indicated by a pre-bronchodilator FEV1 < 80% predicted recorded at Visit 1 or < 90% for patients on oral corticosteroids.
  7. An elevated peripheral blood eosinophil level of ≥ 300/µL that is related to asthma or ≥ 150/µL in patients treated with oral corticosteroids as maintenance therapy demonstrated at visit 1 or in the previous 12 months
  8. Confirmed history of two or more exacerbations requiring treatment with systemic corticosteroids (intramuscular, intravenous, or oral), in the 12 months prior to visit 1, despite the use of high-dose inhaled corticosteroids. For patients receiving maintenance corticosteroids, the corticosteroid treatment for the exacerbations must have been a two-fold increase or greater in the dose.

Exclusion Criteria:

  1. Current smokers or former smokers with a smoking history of ≥ 10 pack years (number of pack years = (number of cigarettes per day / 20) x number of years smoked). Patients who have not smoked for ≥ 6 months before visit 1 and have < 10 pack years can be included into the study.
  2. Presence of a clinically important lung condition other than asthma. This includes current infection, bronchiectasis, pulmonary fibrosis, bronchopulmonary aspergillosis, or diagnoses of emphysema or chronic bronchitis (chronic obstructive pulmonary disease other than asthma) or a history of lung cancer.
  3. Patients who have received omalizumab [Xolair] within 130 days of Visit 1.
  4. Patients who have received any biological to treat inflammatory disease within 5 half-lives of visit 1

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Mepolizumab
100 mg SC every 4 weeks for 13 injections
Arzneimittel: Mepolizumab
100 mg SC every 4 weeks for 13 injections
Experimental: Placebo
Amount of Placebo corresponding to mepolizumab dose SC every 4 weeks for 13 injections
Arzneimittel: Placebo

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
mean change from baseline in pre- and post-bronchodilator FVC at visit 10 (week 24) and at time of response
Zeitfenster: week 24 and time of response
The primary outcome is the mean change from baseline in pre- and post-bronchodilator forced vital capacity (FVC) at visit 10 (week 24) and at time of response
week 24 and time of response
mean change from baseline in pre- and post-bronchodilator FEV1 at visit 10 (week 24) and at time of response
Zeitfenster: week 24 and time of response
The primary outcome is the mean change from baseline in pre- and post-bronchodilator forced expiratory volume in 1 second (FEV1) at visit 10 (week 24) and at time of response
week 24 and time of response
mean change from baseline in pre- and post-bronchodilator RV at visit 10 (week 24) and at time of response
Zeitfenster: week 24 and time of response
The primary outcome is the mean change from baseline in pre- and post-bronchodilator residual volume (RV) at visit 10 (week 24) and at time of response
week 24 and time of response
mean change from baseline in pre- and post-bronchodilator TLC at visit 10 (week 24) and at time of response
Zeitfenster: week 24 and time of response
The primary outcome is the mean change from baseline in pre- and post-bronchodilator total lung capacity (TLC) at visit 10 (week 24) and at time of response
week 24 and time of response
mean change from baseline in pre- and post-bronchodilator airway resistance at visit 10 (week 24) and at time of response
Zeitfenster: week 24 and time of response
The primary outcome is the mean change from baseline in pre- and post-bronchodilator airway resistance at visit 10 (week 24) and at time of response
week 24 and time of response
mean change from baseline in pre- and post-bronchodilator IC at visit 10 (week 24) and at time of response
Zeitfenster: week 24 and time of response
The primary outcome is the mean change from baseline in pre- and post-bronchodilator inspiratory capacity (IC) at visit 10 (week 24) and at time of response
week 24 and time of response
mean change from baseline in pre- and post-bronchodilator CO diffusion capacity at visit 10 (week 24) and at time of response
Zeitfenster: week 24 and time of response
The primary outcome is the mean change from baseline in pre- and post-bronchodilator CO diffusion capacity at visit 10 (week 24) and at time of response
week 24 and time of response

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Mean change from baseline in pre- and post-bronchodilator forced vital capacity (FVC) over the 48-week treatment period at prespecified timepoints (1, 3, 6, 9 and 12 months)
Zeitfenster: 1, 3, 6, 9 and 12 months
1, 3, 6, 9 and 12 months
Mean change from baseline in pre- and post-bronchodilator forced expiratory volume in 1 second (FEV1) over the 48-week treatment period at prespecified timepoints (1, 3, 6, 9 and 12 months)
Zeitfenster: 1, 3, 6, 9 and 12 months
1, 3, 6, 9 and 12 months
Mean change from baseline in pre- and post-bronchodilator residual volume (RV) over the 48-week treatment period at prespecified timepoints (1, 3, 6, 9 and 12 months)
Zeitfenster: 1, 3, 6, 9 and 12 months
1, 3, 6, 9 and 12 months
Mean change from baseline in pre- and post-bronchodilator total lung capacity (TLC) over the 48-week treatment period at prespecified timepoints (1, 3, 6, 9 and 12 months)
Zeitfenster: 1, 3, 6, 9 and 12 months
1, 3, 6, 9 and 12 months
Mean change from baseline in pre- and post-bronchodilator airway resistance over the 48-week treatment period at prespecified timepoints (1, 3, 6, 9 and 12 months)
Zeitfenster: 1, 3, 6, 9 and 12 months
1, 3, 6, 9 and 12 months
Mean change from baseline in pre- and post-bronchodilator inspiratory capacity (IC) over the 48-week treatment period at prespecified timepoints (1, 3, 6, 9 and 12 months)
Zeitfenster: 1, 3, 6, 9 and 12 months
1, 3, 6, 9 and 12 months
Mean change from baseline in pre- and post-bronchodilator CO diffusion capacity over the 48-week treatment period at prespecified timepoints (1, 3, 6, 9 and 12 months)
Zeitfenster: 1, 3, 6, 9 and 12 months
1, 3, 6, 9 and 12 months
Exercise tolerance in a subgroup of patients: Mean change from baseline in exercise endurance time
Zeitfenster: 1, 3, 6, 9 and 12 month
Mean change from baseline in exercise endurance time during a sub-maximal constant-load cycle ergometry test after 1, 3, 6, 9 and 12 months of treatment.
1, 3, 6, 9 and 12 month
Exercise tolerance in a subgroup of patients: Mean change from baseline in inspiratory capacity (IC)
Zeitfenster: 1, 3, 6, 9 and 12 month
Mean change from baseline in inspiratory capacity (IC) at rest and at peak during sub-maximal constant-load cycle ergometry test after 1, 3, 6, 9 and 12 months of treatment.
1, 3, 6, 9 and 12 month
Exercise tolerance in a subgroup of patients: Mean change from baseline in exertional dyspnea and leg discomfort (Borg CR10 Scale®)
Zeitfenster: 1, 3, 6, 9 and 12 month
Mean change from baseline in exertional dyspnea and leg discomfort (Borg CR10 Scale®) during sub-maximal constant-load cycle ergometry test after 1, 3, 6, 9 and 12 months of treatment
1, 3, 6, 9 and 12 month
Time to clinical response and time to change of baseline parameters of clinical Response: sence of smell
Zeitfenster: 52 weeks
52 weeks
Time to clinical response and time to change of baseline parameters of clinical Response: sense of taste
Zeitfenster: 52 weeks
52 weeks
Time to clinical response and time to change of baseline parameters of clinical Response: lung volume
Zeitfenster: 52 weeks
52 weeks
Time to clinical response and time to change of baseline parameters of clinical Response: CO Diffusion capacity
Zeitfenster: 52 weeks
52 weeks
Time to clinical response and time to change of baseline parameters of clinical Response: FEV1 reversibility
Zeitfenster: 52 weeks
52 weeks
Time to clinical response and time to change of baseline parameters of clinical Response: exhaled NO (eNO)
Zeitfenster: 52 weeks
52 weeks
Time to clinical response and time to change of baseline parameters of clinical Response: blood eosinophils
Zeitfenster: 52 weeks
52 weeks
Time to clinical response and time to change of baseline parameters of clinical Response: eosinophilic cationic Protein (ECP)
Zeitfenster: 52 weeks
52 weeks
Time to clinical response and time to change of baseline parameters of clinical Response: blood periostin
Zeitfenster: 52 weeks
52 weeks
Mean change from baseline in Asthma Control Questionnaire (ACQ)
Zeitfenster: 52 weeks
52 weeks
Mean change from baseline in Asthma Quality of Life Questionnaire (AQLQ)
Zeitfenster: 52 weeks
52 weeks
Mean change from baseline in St. George´s Respiratory Questionnaire (SQRG)
Zeitfenster: 52 weeks
52 weeks
Mean change from baseline in Dyspnoe Index (BDI/TDI)
Zeitfenster: 52 weeks
52 weeks
Mean change from baseline in fatique
Zeitfenster: 52 weeks
52 weeks
Mean change from baseline in number of days off school/work over the 48-week treatment period
Zeitfenster: 48 weeks
48 weeks
Time to first clinically significant exacerbation requiring oral or systemic corticosteroids, hospitalization, and/or emergency department (ED) visits
Zeitfenster: 52 weeks
52 weeks
Frequency of clinically significant exacerbations
Zeitfenster: 52 weeks
52 weeks
Time to first exacerbation requiring hospitalization or emergency department (ED) visit
Zeitfenster: 52 weeks
52 weeks
Frequency of exacerbations requiring hospitalization (including intubation and admittance to an intensive care unit (ICU)) or ED visits
Zeitfenster: 52 weeks
52 weeks
GETE rating by physician and patient at time of response and over the 52-week treatment period at pre-specified timepoints (1, 3, 6, 9 and 12 months)
Zeitfenster: 1, 3, 6, 9 and 12 month
1, 3, 6, 9 and 12 month
Mean change in proportion of patients with nasal polyps, chronic sinusitis and loss of smell and taste
Zeitfenster: 52 weeks
52 weeks
Clinical response to mepolizumab in relation to asthma parameters which potentially predict clinical response
Zeitfenster: 52 weeks
Clinical response to mepolizumab in relation to asthma parameters which potentially predict clinical response (age at onset and duration of asthma, prior asthma medication, presence of nasal polyps, sense of smell and taste, allergic sensitization (skin prick test, total and specific IgE against aeroallergens and Staph. aureus enterotoxin), reversibility of airflow obstruction, eNO, blood eosinophils, eosinophilic cationic protein (ECP), blood periostin, ANA, ANCA, ECP.
52 weeks
Routine safety assessment (AE and SAE reporting, withdrawals, pregnancy, hematological and clinical chemistry parameters, ECG and vital signs (pulse rate and systolic and diastolic blood pressure))
Zeitfenster: 52 weeks
Routine safety assessments are incorporated throughout and/or at the end of treatment period including AE and SAE reporting, withdrawals, pregnancy, hematological and clinical chemistry parameters, ECG and vital signs (pulse rate and systolic and diastolic blood pressure).
52 weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Johannes Gutenberg University Mainz

Mitarbeiter

GlaxoSmithKline

Ermittler

  • Hauptermittler: Stephanie Korn, MD, Johannes Gutenberg University Mainz

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

17. November 2015

Primärer Abschluss (Tatsächlich)

22. Mai 2017

Studienabschluss (Tatsächlich)

22. Mai 2017

Studienanmeldedaten

Zuerst eingereicht

31. August 2015

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

2. November 2015

Zuerst gepostet (Schätzen)

3. November 2015

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

13. Juli 2017

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

11. Juli 2017

Zuletzt verifiziert

1. Juli 2017

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • 2015-001
  • 2015-001868-19 (EudraCT-Nummer)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Asthma

Klinische Studien zur Placebo

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Croatia

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren